Claudia Lefeuvre‐Plesse
Centre Eugène Marquis(FR)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology
Most-Cited Works
- → Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer(2019)1,962 cited
- → Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort(2018)277 cited
- → Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016(2020)186 cited
- → Genomics to select treatment for patients with metastatic breast cancer(2022)160 cited
- → Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial(2021)154 cited
- → Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study(2014)55 cited
- → Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database(2021)46 cited
- → LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)(2022)40 cited
- → A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy(2015)37 cited
- → Prognostic and predictive values of oncogenic BRAF, NRAS, c‐KIT and MITF in cutaneous and mucous melanoma(2015)37 cited